Maze Therapeutics’ (MAZE) Buy Rating Reaffirmed at HC Wainwright

Posted by Shane Hupp on Sep 24th, 2026

Maze Therapeutics (NASDAQ:MAZE – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 319.69% from the company’s previous close.

A number of other research firms have also issued reports on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Citigroup initiated coverage on Maze Therapeutics in a report on Wednesday. They set a “buy” rating and a $50.00 price target on the stock. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wedbush reissued an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday. Finally, BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $63.40.

Check Out Our Latest Research Report on MAZE

Maze Therapeutics Stock Performance

Shares of MAZE stock traded down $1.88 during mid-day trading on Thursday, hitting $26.21. 789,176 shares of the stock were exchanged, compared to its average volume of 662,587. The stock’s fifty day simple moving average is $27.18 and its two-hundred day simple moving average is $29.17. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. Maze Therapeutics has a 12-month low of $21.95 and a 12-month high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). On average, analysts forecast that Maze Therapeutics will post -2.72 EPS for the current year.

Insiders Place Their Bets

In other Maze Therapeutics news, CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $26.22, for a total value of $254,465.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 3,243 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $84,350.43. Following the completion of the sale, the insider directly owned 32,316 shares in the company, valued at $840,539.16. This represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 191,459 shares of company stock worth $5,263,539 over the last quarter. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter valued at approximately $48,000. Royal Bank of Canada boosted its holdings in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Maze Therapeutics in the 2nd quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the 4th quarter valued at approximately $145,000. Finally, IFP Advisors Inc purchased a new stake in Maze Therapeutics in the 4th quarter valued at approximately $146,000.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: New bullish coverage: Citigroup and BTIG both initiated coverage with Buy ratings and $50 price targets, providing additional institutional support for Maze’s valuation. Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
Positive Sentiment: Analyst conviction remains strong: HC Wainwright reaffirmed its Buy rating with a $110 target, while Wedbush maintained Outperform with a $48 target. These targets imply substantial potential upside from current trading levels.
Positive Sentiment: Additional coverage momentum: CIBC’s initiation of coverage previously helped Maze shares rise, and analysts continue to highlight the company alongside other healthcare opportunities. Analysts Offer Insights on Healthcare Companies: Maze Therapeutics and Ionis Pharmaceuticals Maze Therapeutics Shares Rise After CIBC Initiates Coverage
Neutral Sentiment: Short-interest data shows no active bearish positioning: Reported short interest was zero shares as of September 24, producing a 0.0-day short-interest ratio. The unusual figure is not a direct catalyst but suggests short covering is unlikely to explain current trading.
Neutral Sentiment: Sector attention: Positive results for a kidney drug at Vertex helped lift another biotechnology company, potentially supporting sentiment toward kidney-disease drug developers, although the report does not identify a direct Maze-specific benefit. Vertex’s Kidney Drug Success Sparks a Surge for a Rival Biotech

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.